Acasti pharma finalized and submitted trilogy 2 statistical analyses plan to fda on july 31

Acasti pharma inc - finalized and submitted trilogy 2 statistical analyses plan to fda on july 31.acasti pharma inc - trilogy 2 topline results expected on or about august 31.acasti pharma inc - as of june 30, 2020, acasti had cash and cash equivalents totaling $12.1 million.acasti pharma inc - believes it is sufficiently funded through first calendar quarter of 2021.
ACST Ratings Summary
ACST Quant Ranking